Regenerative Therapies and Devices

Lead Research Organisation: University of Leeds
Department Name: Mechanical Engineering

Abstract

The Innovation and Knowledge Centre in Regenerative Therapies and Devices will provide a sustainable regional and international platform to address the creation of new technologies in Regenerative Therapies and Devices and their accelerated adoption within a complex global market place with increasing cost constraints. Therapies and devices which facilitate the regeneration of body tissues offer the potential to revolutionise healthcare and be a catalyst for economic growth, creating a new business sector within healthcare technology (Foresight Healthcare 2020). This centre is focused on emerging novel technologies in biological scaffolds, nano-biomaterials and self assembling peptides. These hybrid technologies utilise novel physical and biological functionality to enhance and accelerate the regeneration of tissues by harnessing the potential of endogenous stem cells in vivo. These novel technologies will also provide a vehicle for the delivery of exogenous stem cells to patients in the future and can be used to generate neo-tissues in vitro. The delivery of these emerging technologies to patients will be accelerated by improved diagnostics and imaging for enhanced patient targeting and by new complex simulation methodologies (patient in the lab) for improved short term predictions of the long term clinical outcomes. The life expectancy and average age of the population continues to increase as a result of advances in biomedicine and healthcare and this is generating additional social and economic burden. The Regenerative Technologies and Devices IKC will address the needs and quality of life of the ageing population, and address their expectations of an active lifestyle for fifty more years after fifty . It will specifically, but not exclusively, focus on areas of clinical need in musculoskeletal disease, dentistry, cardiovascular disease and cancer, which have been strategically prioritised by the University and the Leeds Hospitals Trust. The centre will build upon and develop substantial clinical, academic and industry partnerships. Additional new collaborative funding of over 58 million has already been confirmed to match the IKC award, and the centre has plans which have identified research and innovation funding in this area of over 100 million during the initial five year period of its activities.This rapidly growing multidisciplinary area will require innovative scientists and engineers who can cross disciplinary boundaries, work in broader systems based projects and work flexibly and collaboratively with industry and clinicians at different stages of the innovation pipeline. The centre and its partners will develop new and different approaches to innovation at an early stage of the innovation cycle, to substantially accelerate innovation, shorten the time period to clinical trials and market, and mitigate technology risks associated with this emergent sector. Collaborators in the Leeds University Business School will develop and evaluate open innovation methodologies. The University of Leeds is ideally placed to take advantage of this EPSRC call for four important reasons. First it has considerable competency in technology and science, as well as capabilities in managing collaborative innovation and entrepreneurship. Second it has the capability to both manage facilitate and create accelerated innovation in emerging healthcare technologies. Third the University already has excellent facilities and a track record (WRHIP) for innovation and is working with Yorkshire Forward to establish an Innovation Hub in Healthcare Technologies. Fourth the strategic partnership with the Clinical Trials Research Unit and the Unit of Health Economics will enable transition into NHS practice.

Organisations

Publications

10 25 50
publication icon
Abdelgaied A (2014) The effect of insert conformity and material on total knee replacement wear. in Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine

publication icon
Abdelgaied A (2013) Quantification of the effect of cross-shear and applied nominal contact pressure on the wear of moderately cross-linked polyethylene. in Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine

publication icon
Al-Hajjar M (2013) Effect of femoral head size on the wear of metal on metal bearings in total hip replacements under adverse edge-loading conditions. in Journal of biomedical materials research. Part B, Applied biomaterials

publication icon
Al-Hajjar M (2013) Wear of novel ceramic-on-ceramic bearings under adverse and clinically relevant hip simulator conditions. in Journal of biomedical materials research. Part B, Applied biomaterials

publication icon
Bayon Y (2015) Progressing innovation in biomaterials. From the bench to the bed of patients. in Journal of materials science. Materials in medicine

publication icon
Brockett C (2012) Wear of knee prostheses in Orthopedic Research and Reviews

publication icon
Brockett CL (2012) Wear of moderately cross-linked polyethylene in fixed-bearing total knee replacements. in Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine

 
Title Institute promotional video 
Description A 10 minute video has been professionally created to support visits to our facilities. The film showcases a range of stages in career who talk about the research challenges and outputs across the institute. 
Type Of Art Film/Video/Animation 
Year Produced 2013 
Impact Increased number of people requesting visits and lab tours, increased engagement with the Medical Technologies IKC. 
URL https://www.youtube.com/user/MedTechLeeds/videos?view=0
 
Description High quality research and innovation platform
£95m new research income
Established academic supply chain and translational capability across 250 researchers
Active collaborations and technology validation with 9 UK HEIs, 18 academic and clinical partners
New Medical Technologies building and a new post of Director of Innovation in Medical Technologies

Successful sustainable innovation
Defined robust sustainability model
Strategically identified and prioritised key market sectors that offer significant opportunity
Developed a culture of innovation across academic, industry and clinical partnerships
Sharing innovation good practice with 9 UK HEIs and other innovation hubs at Leeds
166 collaborative projects, 66 industry co-investors

Established profile and reputation
Robust brand identity and reach across the UK and beyond through targeted marketing and communications
Strategic alignment with Regener8 giving access to a 240 industry members, 328 academics and 21 clinicians across UK
High profile events with national partners to engage the community in issues that impact on medical and regenerative technology innovation.
Significant political visits and media coverage

Successful innovation and translation
Established Innovation system, pipeline, stage gates and criteria for progression
Defined IP portfolio and directly funded 42 Proof of Concept and 6 Co-Development projects
Pipeline of 166 collaborative innovation projects with industry, of which 48 directly IKC funded
Contributed to the development of 46 new products that have reached the market.
Generated £57m investment in private sector partners for development of our IP/technology and a further £30m plus investment in private sector for development arising out of collaborative projects
Exploitation Route The IKC has a proven system to identify larger collaborative projects with industrial partners. In these larger-scale projects the costs are split equally between ourselves and the Centre's industrial partners. Some of the larger co-development projects include:

- Working with Simulation Solutions to develop an electromechanical knee simulator

- A partnership with Tissue Regenix in the creation of a product for the repair of

damaged or worn knees using Tissue Regenix' proprietary technology platform

- Working alongside credentis ag to further develop self-assembling peptide biomimetic scaffolds for dental repair

- Working with NHS Blood and Transplant to improve processes for allograft tissue banking

The IKC also works with companies to support the development of technology beyond Technology Readiness Level 5 with direct, industry-funded projects that draw upon our unique capability to deliver projects demanded by industry. These are referred to as "late stage innovation" projects where a company directly accesses our expertise to support the development of their IP or to progress product development through independent, validated data from an ISO 9001 accredited and internationally-recognised laboratory
The IKC leads the acceleration of new technologies and innovations to help them reach the marketplace faster. In the first three years the IKC has been involved in 136 projects that have direct industrial investment and engagement.

Whilst our core capabilities in medical device research and development are in great demand, accounting for more than 70 per cent of our projects, our partners are increasingly interested in our knowledge of emerging markets, particularly in the areas of biosensors, stem cell and biological scaffold technologies.

Developing relationships with centres of expertise across the UK has also been central to growth over the past year and we have seen further development of collaborative arrangements with a number of universities, including the Bristol Urological Institute, the University of Cambridge and St Andrews University. We have formed a strategic alliance with Regener8 - the partnership of academics from the eight leading research-intensive universities of the North of England (the N8 Research Partnership) - further strengthening our pool of expertise and resources and increasing our reach to more than 169 companies and more than 30 clinicians
Sectors Healthcare

URL http://www.medical-technologies.co.uk
 
Description High quality research and innovation platform £95m new research income Established academic supply chain and translational capability across 250 researchers Active collaborations and technology validation with 9 UK HEIs, 18 academic and clinical partners New Medical Technologies building and a new post of Director of Innovation in Medical Technologies Successful sustainable innovation Defined robust sustainability model Strategically identified and prioritised key market sectors that offer significant opportunity Developed a culture of innovation across academic, industry and clinical partnerships Sharing innovation good practice with 9 UK HEIs and other innovation hubs at Leeds 166 collaborative projects, 66 industry co-investors Established profile and reputation Robust brand identity and reach across the UK and beyond through targeted marketing and communications Strategic alignment with Regener8 giving access to a 240 industry members, 328 academics and 21 clinicians across UK High profile events with national partners to engage the community in issues that impact on medical and regenerative technology innovation. Significant political visits and media coverage Successful innovation and translation Established Innovation system, pipeline, stage gates and criteria for progression Defined IP portfolio and directly funded 42 Proof of Concept and 6 Co-Development projects Pipeline of 166 collaborative innovation projects with industry, of which 48 directly IKC funded Contributed to the development of 46 new products that have reached the market. Generated £57m investment in private sector partners for development of our IP/technology and a further £30m plus investment in private sector for development arising out of collaborative projects
First Year Of Impact 2010
Sector Healthcare
Impact Types Societal,Economic

 
Description international standards committee chair
Geographic Reach Asia 
Policy Influence Type Membership of a guideline committee
Impact international pre clinical testing standards
 
Description Biomedical research unit
Amount £6,000,000 (GBP)
Funding ID Leeds musculoskeletal biomedical research unit 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2014 
End 03/2017
 
Description CDT 2014-22
Amount £4,000,000 (GBP)
Funding ID CDT TERM 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 06/2014 
End 09/2022
 
Description Capital equipment CDT
Amount £240,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 11/2015 
End 04/2019
 
Description Catalyst Medical Technologies
Amount £3,000,000 (GBP)
Organisation Higher Education Funding Council for England 
Sector Public
Country United Kingdom
Start 10/2015 
End 10/2018
 
Description DTP
Amount £2,000,000 (GBP)
Funding ID DTP 
Organisation DePuy Synthes 
Sector Private
Country United States
Start 01/2014 
End 01/2016
 
Description EPSRC Healthcare Technology Challenge
Amount £1,200,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 04/2013 
End 04/2016
 
Description EPSRC small scale equipment grant
Amount £500,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 01/2012 
End 01/2013
 
Description European Research Council advanced award
Amount £2,000,000 (GBP)
Funding ID Proposal 267114 
Organisation European Research Council (ERC) 
Sector Public
Country European Union (EU)
Start 04/2011 
End 04/2016
 
Description Industry Biocomposites
Amount £150,000 (GBP)
Organisation Biocomposites 
Sector Private
Country United Kingdom
Start 07/2015 
End 07/2016
 
Description Industry Invibio
Amount £300,000 (GBP)
Organisation Invibio 
Sector Private
Country United Kingdom
Start 10/2015 
End 10/2017
 
Description Leeds Musculoskeletal Biomedical Research Centre
Amount £6,000,000 (GBP)
Organisation University of Leicester 
Department NIHR Biomedical Research Centre
Sector Hospitals
Country United Kingdom
Start 04/2017 
End 03/2022
 
Description Mecical technologies Innovation and Knowledge Centre Phase 2 Regenerative Devices
Amount £4,000,000 (GBP)
Funding ID EP/N00941X/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 07/2015 
End 07/2020
 
Description Medcial engineering centre
Amount £160,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 07/2015 
End 07/2019
 
Description Medical Technologies IKC Phase 2 Regenerative Devices
Amount £3,000,000 (GBP)
Funding ID EP/N00941X/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 07/2015 
End 06/2020
 
Description Medical engineering centre
Amount £4,200,000 (GBP)
Funding ID WELMEC 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2014 
End 09/2015
 
Description Optimising knee therapies
Amount £4,000,000 (GBP)
Funding ID EP/P001076/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 09/2016 
End 09/2021
 
Description senior investigator
Amount £100,000 (GBP)
Funding ID LMBRU 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2014 
End 04/2015
 
Title Hip Joint simulator 
Description In vitro simulator for artificial hip joints 
Type Of Material Model of mechanisms or symptoms - in vitro 
Year Produced 2013 
Provided To Others? Yes  
Impact Method commercialised by Simulation Solutions 
 
Title Knee joint simulator 
Description artificial knee joint simulator 
Type Of Material Model of mechanisms or symptoms - in vitro 
Year Produced 2013 
Provided To Others? Yes  
Impact Simulator and simulation method commercialised by simulation solution 
 
Title Natural knee simulator 
Description Simulation system for natural knee 
Type Of Material Model of mechanisms or symptoms - in vitro 
Year Produced 2013 
Provided To Others? Yes  
Impact Simulator commercially available, Simulation Solutions 
 
Title natural hip simulator 
Description Simulation system for natural hip 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2014 
Provided To Others? Yes  
Impact System commercially availa le from Simulation Solutions 
 
Title spine simulator 
Description Spinal disc simulator 
Type Of Material Model of mechanisms or symptoms - in vitro 
Year Produced 2012 
Provided To Others? Yes  
Impact Commercialised by Simulation solutions 
 
Title Biomechanical and biotribological simulation model natural hip 
Description Biomechanical and biotribological model of natural hip 
Type Of Material Computer model/algorithm 
Year Produced 2013 
Provided To Others? Yes  
Impact used in follow on research 
 
Title Biomechanical model of functional spinal unit 
Description model of functional spinal unit 
Type Of Material Computer model/algorithm 
Year Produced 2014 
Provided To Others? Yes  
Impact used in follow on research 
 
Title Biotribological model naturala knee 
Description Biotribological model natural knee 
Type Of Material Computer model/algorithm 
Year Produced 2014 
Provided To Others? Yes  
Impact Used in follow on research on regenerative devices 
 
Title wear simulation model artificial hip 
Description wear simulation model artificial hip 
Type Of Material Computer model/algorithm 
Year Produced 2010 
Provided To Others? Yes  
Impact applied in industry contract research 
 
Title wear simulation model artificial knee 
Description wear simulation model artificial knee 
Type Of Material Computer model/algorithm 
Year Produced 2012 
Provided To Others? Yes  
Impact used in industry contract research 
 
Description Aedstem 
Organisation Aedstem Ltd
Country United Kingdom 
Sector Private 
PI Contribution Diagnostic test for prancreatic islet transplantation
Start Year 2011
 
Description Aesculap 
Organisation Aesculap
Country Germany 
Sector Private 
PI Contribution LifeLongJoints - Silicon Nitride Coatings
Start Year 2013
 
Description Avacta 
Organisation Avacta Group
Country United Kingdom 
Sector Private 
PI Contribution Electronic Biomarker Detection (eTect); Use of spectroscopy for non-invasive phenotyping of stem cells; Use of di-electrophoresis for minimally manipulated stem cell enrichment.
Start Year 2010
 
Description Barco 
Organisation Barco
Country Belgium 
Sector Private 
PI Contribution Leeds Virtual Microscope (LVM) - High Speed Digital Examination of clinical histological samples
Start Year 2011
 
Description Biocomposites Ltd 
Organisation Biocomposites
Country United Kingdom 
Sector Private 
PI Contribution Calcium Phosphate Bone Void Filler - A Pin-on-Plate Study; Calcium Sulphate Bone Void Filler Comparison - A Pin-on-Plate Study
Collaborator Contribution participate in research and publication
Impact Publication
Start Year 2014
 
Description Biomet 
Organisation Biomet, Inc
Department Biomet UK
Country United Kingdom 
Sector Private 
PI Contribution Evaluate biomechanics and tribology of new ankle implant.
Start Year 2011
 
Description Corin 
Organisation Corin Group PLC
Country United Kingdom 
Sector Private 
PI Contribution Metal on metal hip wear
Collaborator Contribution materials
Impact multidiciplinary
Start Year 2009
 
Description Corline 
Organisation Corline
Country Sweden 
Sector Private 
PI Contribution Heparin coated acellular vascular grafts
Start Year 2011
 
Description Credentis 
Organisation Credentis
Country Switzerland 
Sector Private 
PI Contribution Use of Self assembling peptide(SAP) technology for hard tissue engineering (dental applications)
Collaborator Contribution materilas
Impact Ip piublications
Start Year 2014
 
Description DePuy 
Organisation Depuy International
Country United Kingdom 
Sector Private 
PI Contribution Thirty-three projects.
Collaborator Contribution funds , materilas staff
Impact publications
Start Year 2013
 
Description Euro Coatings 
Organisation Euro Coatings
Country United Kingdom 
Sector Private 
PI Contribution Evaluation of coating wear
Start Year 2010
 
Description Geistlich 
Organisation Geistlich
Country Switzerland 
Sector Private 
PI Contribution Use of self assembling peptides in hard tissue engineering (bone)
 
Description Giltech Ltd 
Organisation Giltech
Country United Kingdom 
Sector Private 
PI Contribution Collaboration partner on the "Restoration of lost enamel using engineered acid-resistant and photosensitive minerals and eyesafe pulsed lasers" project
Start Year 2011
 
Description Glass Technology Services Ltd 
Organisation Glass Technology Services
Country United Kingdom 
Sector Private 
PI Contribution Collaboration partner on the "Restoration of lost enamel using engineered acid-resistant and photosensitive minerals and eyesafe pulsed lasers" project.
Start Year 2011
 
Description Invibio 
Organisation Invibio
Country United Kingdom 
Sector Private 
PI Contribution Four projects: PEEK low con knees; Investigation of biocompatibilty of PEEK wear debris; Investigation of PEEK as cervical disc bearing material; Low Cost Polymer Knee
Start Year 2010
 
Description Isogenica 
Organisation Isogenica
Country United Kingdom 
Sector Private 
PI Contribution Combining Novel Invitro display technology with antibody mimetics screening
Start Year 2011
 
Description JRI 
Organisation JRI Orthapaedics
Country United Kingdom 
Sector Private 
PI Contribution Ceramic composite hip wear
Start Year 2009
 
Description LMBRU LTHT 
Organisation Leeds Teaching Hospitals NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution patient specific and population based simulation an d modelling publications and outputs
Collaborator Contribution clinical imaging patient data retrieval bank patient participation
Impact publications simulation methods new standards joint grant applications
Start Year 2015
 
Description M Squared Lasers Ltd 
Organisation M Squared Lasers Ltd
Country United Kingdom 
Sector Private 
PI Contribution Collaboration partner on the "Restoration of lost enamel using engineered acid-resistant and photosensitive minerals and eyesafe pulsed lasers" project
Start Year 2011
 
Description Mathys Medical 
Organisation Mathys
Country Switzerland 
Sector Private 
PI Contribution Four projects including: Evaluation of potential ceramic matrix hips Ceramic matrix composite hip Wear of Experimental Ceramics in Total Hip Replacement - A Hip Joint Simulator Study (Mathys IV) Wear of Experimental Ceramics in Total Hip Replacement - A Hip Joint Simulator Study (Mathys V)
Collaborator Contribution materials , research methods , analysis
Impact papres
Start Year 2013
 
Description NAMSA 
Organisation North American Science Associates Inc
Country United States 
Sector Private 
PI Contribution In vivo testing of dCell bone to detremine osseointegration and biocompatibility
Collaborator Contribution undertaking research work
Impact pubication
Start Year 2015
 
Description NHS NBTS 
Organisation NHS Blood and Transplant (NHSBT)
Department National Blood Service
Country United Kingdom 
Sector Public 
PI Contribution 8 projects in collaboration with NHS NBTS Acellular bone ligament graft (Human) Acellular bone meniscus bone graft (Human) Acellular OC graft (Human) Allo vascular graft Allo heart valve Biocompatibility of acellular allogeanic dermis Acellular allogeneic aorta Development of dCELL bone-patella-bone allograft for anterior cruciate ligament replacement
Collaborator Contribution funds time
Impact multidiciplinary
Start Year 2010
 
Description NHSBT 
Organisation NHS Blood and Transplant (NHSBT)
Country United Kingdom 
Sector Public 
PI Contribution Provision of expertise in tissue decellularisation technology Provision of expertise in tissue characterisation methods
Collaborator Contribution Provision of consented human donor tissues for research and analysis purposes
Impact Publications Wilshaw SP Rooney P. Berry H. Kearney JN. Homer-Vanniasinkam S. Fisher J. Ingham E. Development and Characterisation of acellular allogeneic arterial matrices. Tissue Engineering Part A. 18; 471-483 (2012). Michalopoulos E. Knight RL. Korossis S. Kearney JN. Fisher J. Ingham E. Development of methods for studying the differentiation of human mesenchymal stem cells under cyclic compressive strain. Tissue Engineering Part C Methods. 18; 252-262 (2012) Hogg, P., Rooney, P., Ingham, E., Kearney, JN. Development of a decellularised dermis. Cell & Tissue Banking [Epub 2012] 14(3):465-474 September 2013 Huang, Q., Ingham, E., Rooney, P., Kearney, JN. Production of sterilised decellularisaed tendon allograft for clinical use. Cell Tissue Bank Feb 14, 645-54 (2013). Paniagua Gutierrez, JR., Wilcox-Berry, H Korossis, SA., Mirsadraee, S., Veiga Lopes, S., da Costa, F., Kearney, J., Watterson., K., Fisher, J., Ingham, E. Regenerative potential of low concentration SDS decellularised porcine aortic valved conduits in vivo. Tissue Engineering Part A. 21; 332-342 (2015) Hogg, P., Rooney, P., Leow-Dyke, S., Ingham, E., Kearney, JN. Development of a terminally sterilised decellularised dermis. Cell & Tissue Banking 16; 351-359 (2015).
 
Description Neotherix 
Organisation Neotherix Ltd
Country United Kingdom 
Sector Private 
PI Contribution Repair of oral and peridontal defects using regenerative and antibacterial strategies delivered by a novel tissue scaffold vehicle Polymeric scaffolds functionalised for periodontal repair
Collaborator Contribution materials
Impact multidisciplinary
Start Year 2015
 
Description Neu Biomechanics, BiteCiC 
Organisation Neu Biomechanics
Country United Kingdom 
Sector Private 
PI Contribution Evaluation of coating wear
Start Year 2010
 
Description Nuvasive 
Organisation Nuvasive
Country United States 
Sector Private 
PI Contribution Cellular Characterisation of Osteocel Plus
Collaborator Contribution materials
Impact multidisciplinary engineering medicne
Start Year 2013
 
Description Proctor and Gamble 
Organisation Procter & Gamble
Country United States 
Sector Private 
PI Contribution Electronic Biomarker Detection (eTect)
Start Year 2010
 
Description RD Biomed 
Organisation RD Biomed
Country United Kingdom 
Sector Private 
PI Contribution Use of a novel therapeutic device for treatment of periodontal disease Penetration of a new market (dental) for an existing diagnostic device
Start Year 2010
 
Description Siemens 
Organisation Siemens AG
Country Germany 
Sector Private 
PI Contribution Novel Metal Suppression MRI Biomarkers for Joint Prosthesis
Collaborator Contribution software
Impact publications
Start Year 2013
 
Description Simpleware 
Organisation Simpleware Ltd
Country United Kingdom 
Sector Private 
PI Contribution Development of finite element simulation tools to capture patient variation for the analysis of orthopaedic devices across a patient cohort
Collaborator Contribution software
Impact papers
Start Year 2014
 
Description Simulation Solutions 
Organisation Simulation Solutions
Country United Kingdom 
Sector Private 
PI Contribution 10 projects in collaboration with Simulation Solutions: High flex knee simulator Natural knee simulator Natural hip simulator Natural spine simulator Natural joint friction simulator knee joint simulator SOP for hip simulator SOP for knee simulator Natural Knee Simulation System Electro mechanical hip simulator method SOP and training
Collaborator Contribution equipment development
Impact publications
Start Year 2014
 
Description Smith & Nephew, BiteCiC 
Organisation BITECIC Ltd
Country United Kingdom 
Sector Private 
PI Contribution Evaluate fixation of OC plug
Start Year 2010
 
Description Smith & Nephew, BiteCiC 
Organisation Smith and Nephew
Country United Kingdom 
Sector Private 
PI Contribution Evaluate fixation of OC plug
Start Year 2010
 
Description Surgical Innovations 
Organisation Surgical Innovations
Country United Kingdom 
Sector Private 
PI Contribution A total of 4 collaborations with Surgical Innovations A new Arthroscopic Port for use in Arthroscopic Surgery applications Arthroscopic Port Environment Test Cell Design improvements to existing laparoscopy scissors Intra-Abdominal Platform (IAP) development
Start Year 2010
 
Description TRG 
Organisation Tissue Regenix Ltd
Country United Kingdom 
Sector Private 
PI Contribution Provision of expertise in tissue decellularisation Provision of expertise in tissue characterisation methods
Collaborator Contribution Provision of manufactured products Provision of insight into manufacturing, regulation and marketing of medical devices
Impact Publications Wilshaw SP Rooney P. Berry H. Kearney JN. Homer-Vanniasinkam S. Fisher J. Ingham E. Development and Characterisation of acellular allogeneic arterial matrices. Tissue Engineering Part A. 18; 471-483 (2012). Owen, K., Wilshaw, SP., Homer-Vanniasinkam, S., Bojar, RE., Berry, H. & Ingham, E. Assessment of the antimicrobial activity of acellular vascular grafts. European Journal of Endovascular Surgery. 43; 573-581 (2012). Paniagua Gutierrez, JR., Wilcox-Berry, H Korossis, SA., Mirsadraee, S., Veiga Lopes, S., da Costa, F., Kearney, J., Watterson., K., Fisher, J., Ingham, E. Regenerative potential of low concentration SDS decellularised porcine aortic valved conduits in vivo. Tissue Engineering Part A. 21; 332-342 (2015) Abdelgaied, A., Stanley, M., Galfe, M., Berry, H., Ingham, E., Fisher, J. Comparison of the biomechanical tensile and compressive properties of decellularised and natural porcine meniscus. J. Biomechanics. 48; 1389-1396 (2015).
Start Year 2006
 
Description Tissue Regenix 
Organisation Tissue Regenix Ltd
Country United Kingdom 
Sector Private 
PI Contribution A total of 12 projects collaborating with Tissue Regenix Acellular ligament graft (Animal) Acellular bone meniscus bone graft (Animal) Acellular OC graft (Animal) Xeno vascular patch Xeno heart valve Decellularised bladder Decellularised meniscus (see also 12b) Acellular porcine flexor tendon graft Development of the dCELL Partial Meniscus In vivo testing of dCell bone to determine osseointegration and biocompatibility In vivo evaluation of decellularised porcine pulmonary roots. Long Term Evaluation of an Acellular Bovine Arterial Graft in an Ovine Arteriovenous Access Model
Start Year 2009
 
Description Vascutec 
Organisation Vascutek Ltd
Country United Kingdom 
Sector Private 
PI Contribution Heart valve conduit
Start Year 2010
 
Title Acellular Vascular Products 
Description A product comprising a natural acellular xenogenic vascular tissue matrix having at least an80% reduction in DNA content as compared to an untreated control vascular tissue matrix and being antigenically inert by being substantially free of epitopes capable of reacting with pre-formed human antibodies and also without having the ability to substantially activate complement. The invention also includes methods of preparing such products and uses of the products especially in bypass surgery. 
IP Reference WO2012042250 
Protection Patent application published
Year Protection Granted 2012
Licensed Yes
Impact This IP has been assigned to Tissue Regenix (AIM listed Leeds spin out company), which is developing a portfolio of products based on this IP as well as three other patents we have assigned. Products such as a vascular patch for peripheral vascular reconstruction (clinical trial in 2009).
 
Title Acellular Vascular Products 
Description Method for producing acellular arteries 
IP Reference WO2002096476 
Protection Patent granted
Year Protection Granted 2011
Licensed Yes
Impact Now under commercial development by Tissue Regenix group PLC Also under development by NHS Blood & Transplant Tissue Services for application to allogeneic donor arteries
 
Title Acellular porcine meniscus for meniscal repair/replacement 
Description The present invention relates to a method of preparing a tissue matrix and its subsequent use in the replacement and/or repair of a damaged or defective meniscus. The invention also provides meniscal tissue that is substantially decellularised. 
IP Reference WO2008059244 
Protection Patent granted
Year Protection Granted 2009
Licensed Yes
Impact This IP has supported a spin-out (Tissue Regenix) and its development of products. It is one of the four patents licensed to Tissue Regenix.
 
Title Beta Sheet Tape Ribbons in Tissue Engineering 
Description There is described a material comprising ribbons, fibrils or fibres characterised in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a ß-sheet tape-like substructure. 
IP Reference WO2004007532 
Protection Patent granted
Year Protection Granted 2009
Licensed Yes
Impact A spin-out company (Credentis AG).
 
Title Combination of material for joint prosthesis 
Description An orthopaedic joint prosthesis comprises first and second articulating components having respective bearing surfaces in contact with one another. The material of the first bearing surface (14) comprises a metallic material and the material of the second bearing surface (6) comprises a ceramic material. The hardness of the metallic material is at least about 2500 MPa, and the hardness of the ceramic material is greater than that of the metallic material by at least about 4000 MPa. 
IP Reference WO2001017464 
Protection Patent granted
Year Protection Granted 2006
Licensed Yes
Impact Clinical trials started 2006. Now marketed world wide. FDA IDE study underway in USA. A revenue sharing arrangement is in place between us and DePuy International.
 
Title Composite connective Tissue and Bone Implants 
Description Method for the decellularisation of bone-meniscus-bone; bone-tendon-bone and bone-cartilage 
IP Reference WO2014037713 
Protection Patent application published
Year Protection Granted 2013
Licensed No
Impact Proof of concept phase in large animal model completed for bone-tendon-bone, discussions ongoing with a company on development re licensing
 
Title Composition 
Description The present invention relates to a photosensitive composition comprising synthetic nanocrystalline hydroxyapatite or a synthetic precursor thereof doped with a rare earth ion, the use of the composition in restorative or cosmetic dentistry, a process for preparing the composition and a method of generating an image of an exposed dentinal surface of a tooth. 
IP Reference WO2012046082 
Protection Patent application published
Year Protection Granted 2012
Licensed Yes
Impact This IP is supporting three projects: an EPSRC Health Technology Challenge project, an Innovate UK project, and a European funded Marie-Curie award with industrial partners which aims to produce commercial products. IPGroup and commercialisation team scoping out POC in vivo trial to evaluate the technology with the possibility of forming a spin-out company, two other patents would also be bought into this project.
 
Title Decellularised human livers 
Description The process could be applied to human donor organs thus increasing the number of such organs available for transplantation. This IP has not been patented and may still be confidential. 
IP Reference  
Protection Copyrighted (e.g. software)
Year Protection Granted 2014
Licensed No
Impact Too early for notable impacts.
 
Title Low concentration SDS and Protease inhibitors for decellularisation 
Description A method of preparing matrices or tissue engineered biomaterials for implantation, and in particular to a method of improving decellularisation of matrices or tissue engineered biomaterials prior to implantation. The method employs a single anionic detergent in combination with protease inhibitors. 
IP Reference WO2002096476 
Protection Patent granted
Year Protection Granted 2007
Licensed Yes
Impact A portfolio of products is in development for different clinical needs. A spin-out company has been formed (Tissue Regenix) which has a licence of this and three other patents. Also, this IP has been licensed to NHS Blood and Transplant, Tissue Services, for allografts in the NHS in the UK.
 
Title Magnetometer for medical use 
Description A medical magnetometer (10) comprising one or more induction coils (2) for detecting a time varying magnetic field of a region of a subject's body, such as the heart. Each coil has a maximum outer diameter of 4 to 7 cm, and a configuration such that the ratio of the coil's length to its outer diameter is at least 0.5, and the ratio of the coil's inner diameter to its outer diameter is 0.5 or less. Each induction coil (2) is coupled to a respective detection circuit comprising a low impedance pre-ampiifier (3), a low pass filter (5), a notch filter (6) to remove line noise, and an averaging element (7). Each detection circuit produces an output signal (9) for use to analyse the time varying magnetic field of the region of the subject's body. 
IP Reference WO2014006387 
Protection Patent application published
Year Protection Granted 2014
Licensed Yes
Impact IP is currently licensed to a Leeds spin-out (Creavo Medical Technologies Ltd, previously known as Quantum Imaging Ltd). Primary focus at present is the development of cardiac focussed devices, such as the VitalScan machine to support rule out triaging of patients presenting with chest pain in an emergency room setting.
 
Title Method and apparatus for manipulating particles (DEP-SAW) 
Description This invention relates to a method and apparatus for manipulating particles. The patent has not been published yet so may still be confidential. 
IP Reference  
Protection Copyrighted (e.g. software)
Year Protection Granted 2013
Licensed No
Impact The manipulation of particles finds application in a wide range of fields, many of which are medical in nature.
 
Title Methods and devices for detecting structural changes in a molecule measuring electrochemical impedance 
Description The invention relates to a method of detecting a structural change in a molecule, said molecule being attached to a surface, said surface being electrically conductive, wherein the phase of the electrochemical impedance at said surface is monitored, and wherein a change in the phase in the electrochemical impedance at said surface indicates a change in the structure of said molecule. The invention further relates to methods for making arrays having molecules such as, polypeptides attached to electrically conductive surfaces such as electrodes, and to arrays. 
IP Reference WO2008032066 
Protection Patent application published
Year Protection Granted 2008
Licensed No
Impact This IP should support a spin-out company (Phase DX) in the near future.
 
Title On-chip spectroscopy system 
Description This IP has not been patented and may still be confidential. 
IP Reference  
Protection Protection not required
Year Protection Granted 2008
Licensed No
Impact No notable impacts as yet.
 
Title Orthopaedic medical device 
Description A UK priority patent filing has been made but not yet published. The invention relates to an orthopaedic medical device, in particular an arthroscopic aid, for stimulating the release of cells and/or encouraging migration of cells to a surgical site. 
IP Reference  
Protection Copyrighted (e.g. software)
Year Protection Granted 2014
Licensed No
Impact A first in man clinical trial is being planned.
 
Title Porcine bladder biomaterial 
Description The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularisation is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro. 
IP Reference WO2007110634 
Protection Patent granted
Year Protection Granted 2007
Licensed Yes
Impact This IP has supported a spin-out (Tissue Regenix) and its development of products. It is one of the four patents licensed to Tissue Regenix to date.
 
Title Regional anaesthetic delivery system 
Description Unpatented know-how on a regional anaesthetic delivery system. 
IP Reference  
Protection Copyrighted (e.g. software)
Year Protection Granted 2013
Licensed No
Impact Confidentiality agreements in place with various potential partners but no notable impacts yet.
 
Title Scaffold proteins derived from plant cystatins 
Description The present invention relates to scaffold proteins derived from plant cystatins and to nucleic acids encoding them. The scaffolds are highly stable and have the ability to display peptides. The scaffolds are particularly well suited for constructing libraries, e.g. in phage display or related systems. The invention also related to various uses of the scaffolds, including in therapy, diagnosis, environmental and security monitoring, synthetic biology and research, and to cells and cell cultures expressing the scaffold proteins. 
IP Reference WO2014125290 
Protection Patent application published
Year Protection Granted 2014
Licensed Yes
Impact This IP was exclusively licensed to Avacta Life Sciences Ltd in the field of life sciences research reagents and diagnostics. Avacta pay royalties based on the University providing a screening service to Avacta and also for catalogue sales.
 
Title Surgical Retraction Device and Procedure 
Description The invention provides a retraction device (1) adapted for use in minimally invasive surgery, said device comprising: (a) access means ( 3 ); (b) rigid support means; (c) expandable retraction means (2) comprising a multiplicity of radially oriented members (10); (d) flexible attachment means (6); and (e) a multiplicity of magnetic means, wherein said expandable retraction means in its non- expanded form is attached to said rigid support means by said flexible attachment means and is insertable into a subject through said access means, and wherein said multiplicity of magnetic means are comprised in said expandable retraction means. The invention also provides expandable retraction means comprising a multiplicity of radially oriented members and a method for the use of a retraction device in minimally invasive surgery, the method comprising the steps of providing a retraction device according to the first aspect of the invention, inserting said expandable retraction means via said access means through the cavity wall of a subject, deploying the expandable retraction means in its expanded form, magnetising the tissue to be retracted and attaching the magnetised tissue to the retraction device. The device and method according to the invention satisfy the necessary criteria for use in MIS applications and provide for ease in both manufacture and use, and potential application in many areas of MIS. 
IP Reference WO2017134415 
Protection Patent application published
Year Protection Granted 2012
Licensed No
Impact Two companies are potentially interested in using this IP.
 
Title Tissue sensors for medical diagnosis 
Description Optical sensors for the diagnosis of a range of medical conditions. 
IP Reference  
Protection Protection not required
Year Protection Granted 2012
Licensed No
Impact A licence, with revenue sharing provisions, with another University.
 
Title Ultrasonic modification of soft tissue matrices 
Description The present invention provides a method of, and apparatus for, utilising ultrasonic energy so as to mechanically disrupt the collagenous architecture of biological matrices in a controlled manner so that the tissue can be rapidly recellularised in continuous form. The present invention also provides for the production of tissue matrices with improved recellularisation properties, cell stratification or patterning. 
IP Reference WO2004103461 
Protection Patent granted
Year Protection Granted 2007
Licensed Yes
Impact This IP is used in various of our Proof of Concept projects. It has also supported a spin-out company, and a portfolio of products is under development by them.
 
Title Virtual Microscopy 
Description Computer implemented methods and data processing apparatus are described for displaying virtual slide images. Images of a plurality of slides are automatically displayed in a first region of a display device at a first magnification. The slides comprise all the slides including material from a same specimen. An image of at least one of the slides is displayed in a second region at a second magnification greater than the first magnification. At least the image displayed in the second region is changed responsive to receiving user input. Methods for automatically determining a slide layout pattern and methods for virtually melding glass slide images into a single image are also described. 
IP Reference US8970618 
Protection Patent application published
Year Protection Granted 2011
Licensed No
Impact IP portfolio assigned to Roche (Ventana Medical Systems) as part of asset sale of technology, deal completed July 2015. EP and GB patents still pending. US patent granted.
 
Title Visual parameter optimisation software 
Description Software and an algorithm for use with image analysis/process engineering. 
IP Reference  
Protection Copyrighted (e.g. software)
Year Protection Granted 2013
Licensed No
Impact This software was developed for the optimization of image processing algorithms. Today, this is done in a time-consuming way that relies on trial-and-error. Our software enables users to make better choices of parameter values, to do so faster, and to better understand the influence of the parameters on image processing. The software is applicable to image processing, in general, although our research has focussed on applications in biomedical research.
 
Title Arthroscopic device for stimulating synovial mesenchymal stem cells in the knee 
Description The arthroscopic device is currently (as of Jan 2017) in a small scale clinical evaluation study at Leeds Teaching Hospitals funded through NIHR funded Leeds Musculoskeletal Biomedical Research Unit, led and managed by Prof Dennis McGonagle, Dr Tom Baboolal with Consultant Mr Owen Wall. 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2017
Development Status Actively seeking support
Impact IKC funded Proof of Concept (POC) Project supported early development of the new medical device. This supported device design and testing, prototype manufacture and subsequent manufacture of devices for use in the clinical evaluation. The POC also supported generation of data used in patent filing. 
 
Title Decelularised dermis 
Description Decellularised dermal allograft developed by University of Leeds in collaboration with NHS Blood & Transplant Tissue Services now subject to independent randomised interventional treatment study in patients with diabetic foot ulcers 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2015
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Too early to describe impacts 
URL http://www.isrctn.com/ISRCTN64926597
 
Title ISO accredited simulation test laboratory 
Description ISO accredited simulation test laboratory for pre clinical testing and trials widely used by customers around globe 
Type Support Tool - For Medical Intervention
Current Stage Of Development Wide-scale adoption
Year Development Stage Completed 2013
Development Status Under active development/distribution
Impact uptake by wide range of companies 
 
Title acellular bone 
Description under development and in in vivo trials 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2014
Development Status Under active development/distribution
Impact under development and in animal trials 
 
Title acellular bone cartilage osteochondral graft 
Description under development 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Initial development
Year Development Stage Completed 2014
Development Status Under active development/distribution
Impact under developemnt 
 
Title acellular bone cartilage osteochondral graft 
Description under development NHSBT 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Initial development
Year Development Stage Completed 2015
Development Status Under active development/distribution
Impact under development 
 
Title acellular bone patellar bone graft 
Description under development by NHSBT 
Type Therapeutic Intervention - Surgery
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2014
Development Status Under active development/distribution
Impact under development by NHSBT 
 
Title acellular dcell vascular patch 
Description licensed to and commercialised by Tissue Regenix 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Small-scale adoption
Year Development Stage Completed 2010
Development Status Under active development/distribution
Clinical Trial? Yes
Impact First dcell clinical product 
URL https://clinicaltrials.gov/show/NCT00958230
 
Title acellular dcell dermis 
Description commercialised by Tissue regenix from 2014 
Type Therapeutic Intervention - Medical Devices
Year Development Stage Completed 2014
Development Status Under active development/distribution
Impact sold and distributed in USA 
 
Title acellular dermis 
Description supplied as clinical product by NHSBT 
Type Therapeutic Intervention - Surgery
Current Stage Of Development Small-scale adoption
Year Development Stage Completed 2014
Development Status Under active development/distribution
Impact supplied by NHSBT, improved wound healing in chronic leg ulcers 
 
Title acellular heart valve 
Description clinical application through human tissue bank 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Small-scale adoption
Year Development Stage Completed 2010
Development Status Under active development/distribution
Impact proof of clinical use acellular technology 
 
Title acellular vascular graft 
Description under development by NHSBT and Tissue Regenix 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2014
Development Status Under active development/distribution
Impact Under development by NHSBT an dTissue Regenix 
 
Title all polymer knee 
Description collaborative development with Invibio 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Initial development
Year Development Stage Completed 2015
Development Status Under active development/distribution
Impact collaborative development with Invibio 
 
Title ceramic on ceramic hip 
Description Mathys 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Market authorisation
Year Development Stage Completed 2012
Development Status Under active development/distribution
Impact successfully adopted an d commercilised 
 
Title ceramic on ceramic and ceramic on metal hip 
Description commercialised by DePuy and by Mathys 
Type Therapeutic Intervention - Medical Devices
Year Development Stage Completed 2015
Development Status Under active development/distribution
Impact successfully adopted an d commercilised 
 
Title dcell ligament 
Description Under commercial development by tissue Regenix, progressing to CE mark and product launch 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2014
Development Status Under active development/distribution
Clinical Trial? Yes
Impact under commercial development by Tissue Regenix in clinical trial started 2015 proceeding to Ce mark and product launch 2017 
URL https://clinicaltrials.gov/show/NCT02540811
 
Title dcell meniscus 
Description Developed by tissue Regenix In clinical trial started 2015 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2014
Development Status Under active development/distribution
Clinical Trial? Yes
Impact first in man clinical trial started 2015 
URL https://clinicaltrials.gov/show/NCT02270905
 
Title finite element simulation tools to capture patient variation for the analysis of orthopaedic devices across a patient cohort 
Description This project has been led by Dr Ruth Wilcox in partnership with Simpleware Limited. The development of the software add-on has been completed and the final validations with the Leeds data set-set are coming to an end. It is anticipated that a technology demonstrator project will now be undertaken with a company that can demonstrate the utility of the software for evaluating spinal implants. The commercial team is now engaged and discussions with Simpleware around a possible license deal are on-going. It is envisaged that as part of this license deal Simpleware will engage Leeds expertise as part of their offer to companies. In addition Leeds personnel will retain the right to undertake consultancy in their own capacity. 
Type Of Technology Software 
Year Produced 2013 
Impact further research 
 
Title hip joint simulator 
Description hip joint simulator 
Type Of Technology Physical Model/Kit 
Year Produced 2012 
Impact commercial product Simulation solutions 
 
Title knee joint simulator 
Description knee joint simulator 
Type Of Technology Physical Model/Kit 
Year Produced 2013 
Impact Commercial product simulation solutions 
 
Title natural hip simulator 
Description natural hip simulator 
Type Of Technology Physical Model/Kit 
Year Produced 2014 
Impact commercial product simulation solutions 
 
Title natural knee simulator 
Description natural knee simulator 
Type Of Technology Physical Model/Kit 
Year Produced 2013 
Impact commercialised by simulation solutions 
 
Title spinal disc simulator 
Description spinal disc simulator 
Type Of Technology Physical Model/Kit 
Year Produced 2010 
Impact commercial product simulation solutions 
 
Company Name Creavo Medical Technologies Ltd (formerly Quantum Imaging) 
Description Creavo Medical Technologies Ltd is a UK-based, privately held medical device company engaged in the development of innovative imaging technologies. The company was formed to commercialise sensor technology developed by Professor Ben Varcoe, Chair of Quantum Information Science at Leeds University and has facilities in Leeds and in Warwickshire UK. The first application of this technology will be to aid the rapid triage and identification of patients presenting to Emergency Departments with chest pain, but who ultimately have no cardiac related diagnosis. Identifying these patients early enables them to leave expensive cardiac diagnostic pathways so releasing resources to focus on other acute patients. Creavo Medical Technologies has an experienced management team, with a mix of fundamental research, medical device commercialisation, manufacturing and global regulatory and clinical strategy. 
Year Established 2014 
Impact A new cardiac scanning device that could save the NHS £200 million a year is being trialled at four of the UK's largest emergency departments (Bristol, Nottingham, Leicester and Sheffield). The British-made Vitalscan device, which has been developed by Creavo Medical Technologies and could revolutionise the way patients with chest pain are managed in emergency departments, works by conducting a non-invasive three to five-minute scan at a patient's bedside to rule out significant cardiac conditions, such as heart attacks. Data from the York Health Economics Consortium shows that 1.3 million A&E admissions in 2014/15 were due to chest pain. Of these, 63% ultimately had no cardiac-related condition but, the majority would still have gone through the same costly cardiac triage process of someone having a heart attack. Vitalscan has the potential to identify a significant proportion of these patients which would radically change the management of chest pain patients entering emergency departments. Conservative estimates indicate that the device could save the NHS £200 million a year, the equivalent of £3.85 million a week and £382 a minute, easing pressure on bed space in A&E departments and reducing patient anxiety by getting patients to the correct treatment more quickly. Steve Parker, CEO Creavo Medical Technologies says: "Cardiac-related chest pain is one of the biggest issues facing emergency departments in the western world due to the economic burden it places on healthcare services and the disruption it causes to inpatient care. "The triage process for someone entering an emergency department with chest pain can take anywhere from six to 24 hours which places a huge amount of strain on resources. "Early results from smaller sets of clinical trials indicate that Vitalscan can quickly identify and rule out significant ischemic heart disease so it prevents patients who aren't suffering from a cardiac-related condition from having to go through the lengthy, costly chest pain triage process, easing the burden on emergency departments at a time when they are facing unprecedented pressures." Creavo Medical Technologies was established to commercialise the work undertaken by Professor Ben Varcoe at the University of Leeds to develop Vitalscan, a portable, passive magnetocardiography device that measures the electromagnetic fluctuations of the heart, while maintaining the accuracy and efficacy of older SQUID devices. The start of clinical trials at Sheffield Teaching Hospitals NHS Foundation Trust, University Hospitals of Leicester NHS Trust, North Bristol NHS Trust and Nottingham University Hospitals NHS Trust marks the largest ever clinical trial of a magnetocardiography device. This will be followed by a second stage starting at three centres in the United States at Mayo Clinic Rochester, Cincinnati and Baylor Texas.
Website http://creavomedtech.com/
 
Company Name Tissue Regenix 
Description Developemnt and manufacture of Regenerative Biological Scaffolds for tissue repair in vascular, cardiovascular and musculoskeletal systems 
Year Established 2007 
Impact aim listed d raised £0m investment value £150m 4 clinical products
 
Company Name Relitect Ltd 
Description Relitect Ltd are developing a novel technology for the detection of binding events, which can be used for the analysis of proteins, small molecules and nucleic acids. The Relitect proprietary technology enables highly sensitive detection of biomarkers or other analytes in a label free multiplexed format, using small sample volumes. Relitect's approach has potential for utilisation across the clinical diagnostics and life sciences industries. 
Year Established 2014 
Impact March 2015 - Relitect secured a £750K tranched investment from IP Group Plc and Scottish Enterprise's investment arm, the Scottish Investment Bank to develop its novel high sensitivity diagnostic/science technology. 20th April 2015 - Relitect moves to new laboratory facilities at Biocity Scotland -www.biocity.co.uk/biocity/scotland
Website http://www.relitect.com/
 
Description Bridging the gap in translating regenerative therapies 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact An article on the POC funding available to the N8 universities to progress projects with significant commercial potential.

Proof of Concept projects were funded.
Year(s) Of Engagement Activity 2013
 
Description Could Regenerative Medicine help heal UK economy? 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact BBC Online featured the story on Eileen Ingham's spin out company, Tissue Regenix:
The regenerative medicine industry has "huge potential" to boost the UK economy, the managing director of Tissue Regenix has said.



Antony Odell told the BBC's Hugh Pym that the research expertise of the UK has "enormous" potential to create jobs and revenue.

Initiated interest in the University of Leeds and the Medical Technologies IKC
Year(s) Of Engagement Activity 2012
 
Description Healthcare Innovation Expo, ExCel London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Europe's largest, most exciting healthcare innovation event 13th & 14th March 2013.
The IKC hosted an exhibition stand at the event to connect to potential clinical partners.

Initiated new contacts and potential collaborations.
Year(s) Of Engagement Activity 2013
 
Description Innovate 13, Business Design Centre, London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The UK's leading multi-sector innovation & trade event for business. The IKC exhibited at this event.

Initiated new contacts and potential new collaborations
Year(s) Of Engagement Activity 2013
 
Description Interviews on academic/industry collaboration 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact A series of video interviews were created with representatives from partner companies and funders that raises the profile of the benefits of industry/academia collaboration.

Initiated interest in the University of Leeds and the Medical Technologies IKC
Year(s) Of Engagement Activity 2012
 
Description Professor John Fisher appointed to Board of Marketing Leeds 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Deputy Vice-Chancellor and IKC Academic Director, Professor John Fisher, has been appointed as a non-executive director of Marketing Leeds.
In a major move to refocus and provide strategic leadership to Marketing Leeds as it moves forward with a broader role to attract inward investment and tourism, it has announced the appointment of nine Non-Executive Directors.



The Board will oversee a series of programmes and initiatives as Marketing Leeds widens its focus to drive economic growth in the city and ensure Leeds achieves its ambition to be the best city in the UK.



Professor John Fisher will represent the University and its key capabilities of innovation and collaboration with industry, aligning well with the Medical Technologies IKC mission to bring together businesses and our world-class experts to accelerate the commercial development of new products and services.



The new Board members commenced their role with immediate effect. . Awarding Body - Leeds and Partners, Name of Scheme - Non-executive Board of Directors

Initiated interest in the University of Leeds and the Medical Technologies IKC
Year(s) Of Engagement Activity 2012
 
Description Regen Med Nears the Market 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Article published by Genetic Engineering and Biotechnology news about the IKC and Regener8.

Increased number of people visiting website.
Year(s) Of Engagement Activity 2012
 
Description United States link up could pay off for medical park plans - Yorkshire Post 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact The work led by Ceri Williams of the IKC is included in this write up in the Yorkshire Post around inward investment to Leeds from the USA.

Initiated interest in the Medical Technologies IKC
Year(s) Of Engagement Activity 2013
 
Description University Spin-outs - Yorkshire Post 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact An article on the regions most successful university spin-outs featuring Tissue Regenix.

Initiated interest in the University of Leeds and Medical Technologies IKC
Year(s) Of Engagement Activity 2013
 
Description University helps improve medical devices - Yorkshire Post 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Story on the output of project POC018 - Electromechanical hip simulator method SOP (standard operating procedure) and training.
The story covered how the research and project is helping improve safety in medical devices in China.

Initiated new contacts and interest in the Medical Technologies IKC
Year(s) Of Engagement Activity 2013
 
Description Who wants to live forever? 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact ITV Tonight Programme, aired 7:30pm, Thursday 5 July 2012.
A look at how thousands are now celebrating their one hundredth birthday. John Fisher and Eileen Ingham present their research around "50 Active years after 50" as part of the programme.

Initiated interest in the University of Leeds and the Medical Technologies IKC
Year(s) Of Engagement Activity 2012